Zimmer Biomet Holdings, Inc. $ZBH Shares Sold by American Century Companies Inc.

Key Points

• American Century Companies Inc. has reduced its holdings in Zimmer Biomet Holdings, Inc. by 11.3%, selling 670,930 shares during the first quarter, thereby owning approximately 2.65% of the company.
• Zimmer Biomet's recent quarterly earnings report showed an earnings per share (EPS) of $2.07, beating the consensus estimate by $0.09, with revenue up 7.0% year-over-year.
• The company declared a quarterly dividend of $0.24 per share, which reflects a 0.9% dividend yield and a payout ratio of 23.36%.

American Century Companies Inc. trimmed its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 11.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,250,467 shares of the medical equipment provider's stock after selling 670,930 shares during the quarter. American Century Companies Inc. owned approximately 2.65% of Zimmer Biomet worth $594,248,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of ZBH. Garde Capital Inc. acquired a new position in Zimmer Biomet in the 1st quarter valued at $29,000. Menard Financial Group LLC acquired a new position in Zimmer Biomet in the 4th quarter valued at $30,000. Washington Trust Advisors Inc. acquired a new position in Zimmer Biomet in the 1st quarter valued at $30,000. Columbia River Financial Group LLC acquired a new position in Zimmer Biomet in the 1st quarter valued at $30,000. Finally, Accent Capital Management LLC acquired a new position in Zimmer Biomet in the 1st quarter valued at $35,000. 88.89% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ZBH has been the topic of several recent research reports. Raymond James Financial boosted their price objective on shares of Zimmer Biomet from $104.00 to $113.00 and gave the company an "outperform" rating in a research note on Friday, August 8th. Robert W. Baird dropped their price objective on shares of Zimmer Biomet from $130.00 to $115.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 6th. Wells Fargo & Company decreased their target price on shares of Zimmer Biomet from $113.00 to $98.00 and set an "equal weight" rating on the stock in a research report on Tuesday, May 6th. Truist Financial set a $101.00 target price on shares of Zimmer Biomet in a research report on Tuesday, May 6th. Finally, Evercore ISI decreased their target price on shares of Zimmer Biomet from $102.00 to $96.00 and set an "in-line" rating on the stock in a research report on Tuesday, July 8th. Nine research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $111.44.

Zimmer Biomet Price Performance

Shares of Zimmer Biomet stock traded up $1.4760 on Wednesday, hitting $105.7860. The company's stock had a trading volume of 591,224 shares, compared to its average volume of 2,058,366. Zimmer Biomet Holdings, Inc. has a 52-week low of $89.22 and a 52-week high of $116.71. The company has a quick ratio of 0.96, a current ratio of 1.87 and a debt-to-equity ratio of 0.54. The firm has a fifty day moving average price of $94.74 and a 200-day moving average price of $99.30. The company has a market capitalization of $20.96 billion, a P/E ratio of 25.73, a price-to-earnings-growth ratio of 2.02 and a beta of 0.68.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported $2.07 EPS for the quarter, topping the consensus estimate of $1.98 by $0.09. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The business had revenue of $2.08 billion for the quarter, compared to analyst estimates of $2.06 billion. During the same period in the previous year, the firm earned $2.01 EPS. The business's revenue for the quarter was up 7.0% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, equities research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, July 31st. Shareholders of record on Thursday, June 26th were issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date was Thursday, June 26th. Zimmer Biomet's dividend payout ratio is 23.36%.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, insider Sang Yi sold 1,000 shares of the company's stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $95.00, for a total value of $95,000.00. Following the transaction, the insider directly owned 20,424 shares in the company, valued at approximately $1,940,280. This represents a 4.67% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.70% of the company's stock.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.